Meiji Seika Pharma Receives Regulatory Approval in Japan for Two-Dose Vial of KOSTAIVE®, a Self-Amplifying mRNA COVID-19 Vaccine

Reuters

08/29

Meiji Seika Pharma Receives Regulatory Approval in Japan for Two-Dose Vial of KOSTAIVE®, a Self-Amplifying mRNA COVID-19 Vaccine

Meiji Seika Pharma Co., Ltd., in collaboration with Arcturus Therapeutics Holdings Inc., has received manufacturing and marketing approval in Japan for a two-dose vial of KOSTAIVE®, a self-amplifying mRNA COVID-19 vaccine. This approval, dated August 28, highlights the vaccine's capacity to induce neutralizing antibodies against various SARS-CoV-2 variants, including Omicron sub lineage JN.1 variant XEC, LP.8.1, and the currently circulating XFG and NB.1.8.1. The company plans to begin supplying the vaccine in late September 2025, emphasizing its commitment to combating COVID-19.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcturus Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193805-25-001247), on August 29, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2563498770"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2563498770\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2563498770?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-29 18:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2563498770","market":"fut","top_or_hot":-1,"title":"Meiji Seika Pharma Receives Regulatory Approval in Japan for Two-Dose Vial of KOSTAIVE®, a Self-Amplifying mRNA COVID-19 Vaccine","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Meiji Seika Pharma Receives Regulatory Approval in Japan for Two-Dose Vial of KOSTAIVE®, a Self-Amplifying mRNA COVID-19 Vaccine\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Meiji Seika Pharma Co., Ltd., in collaboration with Arcturus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Holdings Inc., has received manufacturing and marketing approval in Japan for a two-dose vial of KOSTAIVE®, a self-amplifying mRNA COVID-19 vaccine. This approval, dated August 28, highlights the vaccine's capacity to induce neutralizing antibodies against various SARS-CoV-2 variants, including Omicron sub lineage JN.1 variant XEC, LP.8.1, and the currently circulating XFG and NB.1.8.1. The company plans to begin supplying the vaccine in late September 2025, emphasizing its commitment to combating COVID-19.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcturus Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193805-25-001247), on August 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meiji Seika Pharma Receives Regulatory Approval in Japan for Two-Dose Vial of KOSTAIVE®, a Self-Amplifying mRNA COVID-19 Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeiji Seika Pharma Receives Regulatory Approval in Japan for Two-Dose Vial of KOSTAIVE®, a Self-Amplifying mRNA COVID-19 Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-29 18:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Meiji Seika Pharma Receives Regulatory Approval in Japan for Two-Dose Vial of KOSTAIVE®, a Self-Amplifying mRNA COVID-19 Vaccine\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Meiji Seika Pharma Co., Ltd., in collaboration with Arcturus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Holdings Inc., has received manufacturing and marketing approval in Japan for a two-dose vial of KOSTAIVE®, a self-amplifying mRNA COVID-19 vaccine. This approval, dated August 28, highlights the vaccine's capacity to induce neutralizing antibodies against various SARS-CoV-2 variants, including Omicron sub lineage JN.1 variant XEC, LP.8.1, and the currently circulating XFG and NB.1.8.1. The company plans to begin supplying the vaccine in late September 2025, emphasizing its commitment to combating COVID-19.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcturus Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193805-25-001247), on August 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARCT","symbol_name":"Arcturus Therapeutics Ltd.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nNDLbqMHKt:1","article_id":"2563498770","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2563498770","pubTimestamp":1756462248,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Meiji Seika Pharma Receives Regulatory Approval in Japan for Two-Dose Vial of KOSTAIVE, a Self-Amplifying mRNA COVID-19 Vaccine. Meiji Seika Pharma Co., Ltd., in collaboration with Arcturus Therapeutics Holdings Inc., has received manufacturing and marketing approval in Japan for a two-dose vial of KOSTAIVE, a self-amplifying mRNA COVID-19 vaccine. This approval, dated August 28, highlights the vaccine's capacity to induce neutralizing antibodies against various SARS-CoV-2 variants, including Omicron sub lineage JN.1 variant XEC, LP.8.1, and the currently circulating XFG and NB.1.8.1. The company plans to begin supplying the vaccine in late September 2025, emphasizing its commitment to combating COVID-19.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARCT":"Arcturus Therapeutics Ltd.","LU0256331488.USD":"SCHRODER ISF GLOBAL ENERGY \"A\" ACC","BK4213":"石油与天然气的勘探与生产","BK4588":"碎股","LU0300736062.USD":"FRANKLIN NATURAL RESOURCES \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","BK4139":"生物科技","LU0300736492.USD":"FRANKLIN NATURAL RESOURCES \"A\" (USD) INC","CTRA":"Coterra Energy Inc."},"translate_title":"Meiji Seika Pharma的KOSTAIVE两剂小瓶获得日本监管机构批准®，一种自扩增mRNA新冠疫苗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARCT":0.9,"CTRA":0.9},"content_text":"Meiji Seika Pharma Receives Regulatory Approval in Japan for Two-Dose Vial of KOSTAIVE®, a Self-Amplifying mRNA COVID-19 Vaccine\n    \n\n        Meiji Seika Pharma Co., Ltd., in collaboration with Arcturus Therapeutics Holdings Inc., has received manufacturing and marketing approval in Japan for a two-dose vial of KOSTAIVE®, a self-amplifying mRNA COVID-19 vaccine. This approval, dated August 28, highlights the vaccine's capacity to induce neutralizing antibodies against various SARS-CoV-2 variants, including Omicron sub lineage JN.1 variant XEC, LP.8.1, and the currently circulating XFG and NB.1.8.1. The company plans to begin supplying the vaccine in late September 2025, emphasizing its commitment to combating COVID-19.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcturus Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193805-25-001247), on August 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}